This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

ARCHIBALD FLETCHER, M.D.; M. MICHAEL SIGEL, Ph.D.; H. A. ZINTEL, M.D.

AMA Arch Surg. 1951;62(2):239-250.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

AFTER the definition of lymphogranuloma venereum as a clinical entity in 1913¹ and the development of a diagnostic skin test in 1925,² the disease received wide recognition and numerous therapeutic agents were used in attempts to cure it. Indifferent results were obtained until the advent of sulfanilamide, which proved encouraging in the experience of early investigators.³ Although later reports of the cumulative experience were less optimistic,⁴ administration of the sulfonamides remained the treatment of choice, since some virustatic properties were demonstrated and secondary infection was controlled. Penicillin showed slight promise,^{4a, d} and streptomycin has had little clinical trial.

The discovery of aureomycin⁵ and the demonstration of its activity against rickettsias and certain virus infections⁶ led to the early clinical trial of this agent in the treatment of lymphogranuloma venereum by Wright and his associates.⁷ They reported the early results in the treatment . . . [Full Text PDF of this Article]

Author Affiliations
PHILADELPHIA

From the Harrison Department of Surgical Research and the Children's Hospital of Philadelphia (Department of Pediatrics) School of Medicine, University of Pennsylvania.

Footnotes
The complement fixation studies described in this paper were supported by the Office of Naval Research.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati     What's this?